Research programme: hepatitis B therapeutics - REPLICor

Drug Profile

Research programme: hepatitis B therapeutics - REPLICor

Alternative Names: REP 9C analogue

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator REPLICor; University of Adelaide
  • Class Nucleic acids; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in Canada (Intraperitoneal)
  • 09 Nov 2015 REPLICor receives patent allowance for methods of combination therapy using immunotherapeutic agents and agents that lower serum HBsAg in USA
  • 17 Apr 2008 Preclinical trials in Hepatitis B in Canada (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top